Difference between revisions of "Gestational trophoblastic neoplasia"
Jump to navigation
Jump to search
m (→Guidelines) |
|||
| Line 56: | Line 56: | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/0020-7292(89)90779-0 Homesley et al. 1988] | ||
| + | | style="background-color:#91cf61" |Phase II | ||
| + | | style="background-color:#d3d3d3" | | ||
| + | | style="background-color:#d3d3d3" | | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG 0174)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG 0174)] | ||
| Line 63: | Line 68: | ||
|- | |- | ||
|} | |} | ||
| + | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.'' | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Methotrexate (MTX)]] 30 mg/m<sup>2</sup> IM once per week | *[[Methotrexate (MTX)]] 30 mg/m<sup>2</sup> IM once per week | ||
| Line 68: | Line 74: | ||
'''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | '''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | ||
===References=== | ===References=== | ||
| + | # Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8. [https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/0020-7292(89)90779-0 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2457192 PubMed] | ||
# '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21263100 PubMed] | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21263100 PubMed] | ||
Revision as of 22:08, 9 December 2018
| Section editor | |
|---|---|
 |
Summer B. Dewdney, MD Chicago, IL |
4 regimens on this page
6 variants on this page
|
Guidelines
ESMO
- 2013: Seckl et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
NCCN
Low-risk disease, all lines of therapy
Dactinomycin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Osborne et al. 2011 (GOG 0174) | Phase III (E) | Methotrexate | Seems to have superior CR rate |
Chemotherapy
- Dactinomycin (Cosmegen) 1.25 mg/m2 IV push once every 2 weeks
Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- GOG 0174: Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed
Methotrexate monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Homesley et al. 1988 | Phase II | ||
| Osborne et al. 2011 (GOG 0174) | Phase III (C) | Dactinomycin | Seems to have inferior CR rate |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Methotrexate (MTX) 30 mg/m2 IM once per week
Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8. link to original article PubMed
- GOG 0174: Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed